FI4214202T3 - Cdk4-estäjän kiinteät muodot - Google Patents
Cdk4-estäjän kiinteät muodot Download PDFInfo
- Publication number
- FI4214202T3 FI4214202T3 FIEP21783049.6T FI21783049T FI4214202T3 FI 4214202 T3 FI4214202 T3 FI 4214202T3 FI 21783049 T FI21783049 T FI 21783049T FI 4214202 T3 FI4214202 T3 FI 4214202T3
- Authority
- FI
- Finland
- Prior art keywords
- cancer
- crystalline form
- ppm
- values
- wavenumber
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078636P | 2020-09-15 | 2020-09-15 | |
| US202163240268P | 2021-09-02 | 2021-09-02 | |
| PCT/IB2021/058320 WO2022058871A1 (en) | 2020-09-15 | 2021-09-13 | Solid forms of a cdk4 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4214202T3 true FI4214202T3 (fi) | 2025-04-25 |
Family
ID=78000744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21783049.6T FI4214202T3 (fi) | 2020-09-15 | 2021-09-13 | Cdk4-estäjän kiinteät muodot |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12570641B2 (enExample) |
| EP (2) | EP4578450A3 (enExample) |
| JP (2) | JP7260606B2 (enExample) |
| KR (1) | KR20230069983A (enExample) |
| CN (1) | CN116507620B (enExample) |
| AU (1) | AU2021345531B2 (enExample) |
| DK (1) | DK4214202T3 (enExample) |
| ES (1) | ES3022913T3 (enExample) |
| FI (1) | FI4214202T3 (enExample) |
| HU (1) | HUE070846T2 (enExample) |
| MX (1) | MX2023003054A (enExample) |
| PL (1) | PL4214202T3 (enExample) |
| PT (1) | PT4214202T (enExample) |
| SI (1) | SI4214202T1 (enExample) |
| TW (2) | TW202334125A (enExample) |
| WO (1) | WO2022058871A1 (enExample) |
| ZA (1) | ZA202303655B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111655295B (zh) | 2018-08-29 | 2024-05-28 | 荣昌生物制药(烟台)股份有限公司 | 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途 |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| MX2023003054A (es) | 2020-09-15 | 2023-04-05 | Pfizer | Formas solidas de un inhibidor de cdk4. |
| AU2022400308B2 (en) * | 2021-12-02 | 2026-02-12 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| JP2025533719A (ja) | 2022-07-29 | 2025-10-09 | ファイザー・インク | がんの治療のためのｋａｔ６阻害剤を含む投与レジメン |
| KR20250054814A (ko) * | 2022-09-05 | 2025-04-23 | 티와이케이 메디슨즈, 인코포레이티드 | Cdk4 키나아제 억제제로 사용되는 화합물 및 이의 용도 |
| KR20250164842A (ko) | 2023-03-30 | 2025-11-25 | 화이자 인코포레이티드 | Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법 |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| EP4719405A1 (en) | 2023-06-02 | 2026-04-08 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| JP2026519559A (ja) | 2023-06-02 | 2026-06-16 | ファイザー・インク | エストロゲン受容体分解薬およびｃｄｋ４阻害剤の組合せ |
| TW202513069A (zh) | 2023-07-21 | 2025-04-01 | 美商冰洲石生物科技公司 | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 |
| WO2025104624A1 (en) | 2023-11-14 | 2025-05-22 | Pfizer Inc. | Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol |
| WO2025202900A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors for use in the treatment of mantle cell lymphoma |
| WO2025202871A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2026025013A2 (en) | 2024-07-26 | 2026-01-29 | Pfizer Inc. | Combination therapy using cdk4 inhibitors for cancer treatments |
| WO2026133192A1 (en) | 2024-12-20 | 2026-06-25 | Pfizer Inc. | Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| TW201105669A (en) | 2009-07-30 | 2011-02-16 | Irm Llc | Compounds and compositions as Syk kinase inhibitors |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| CN105111191B (zh) | 2015-07-21 | 2018-06-08 | 上海皓元生物医药科技有限公司 | 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途 |
| SG11201900328WA (en) | 2016-07-13 | 2019-02-27 | Jason Marineau | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN109803968A (zh) | 2016-08-15 | 2019-05-24 | 辉瑞公司 | 吡啶并嘧啶酮cdk2/4/6抑制剂 |
| CN118286225A (zh) | 2018-04-26 | 2024-07-05 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
| MX2023003054A (es) | 2020-09-15 | 2023-04-05 | Pfizer | Formas solidas de un inhibidor de cdk4. |
-
2021
- 2021-09-13 MX MX2023003054A patent/MX2023003054A/es unknown
- 2021-09-13 EP EP25153633.0A patent/EP4578450A3/en not_active Withdrawn
- 2021-09-13 PT PT217830496T patent/PT4214202T/pt unknown
- 2021-09-13 AU AU2021345531A patent/AU2021345531B2/en active Active
- 2021-09-13 DK DK21783049.6T patent/DK4214202T3/da active
- 2021-09-13 EP EP21783049.6A patent/EP4214202B1/en active Active
- 2021-09-13 HU HUE21783049A patent/HUE070846T2/hu unknown
- 2021-09-13 CN CN202180071477.7A patent/CN116507620B/zh active Active
- 2021-09-13 SI SI202130288T patent/SI4214202T1/sl unknown
- 2021-09-13 ES ES21783049T patent/ES3022913T3/es active Active
- 2021-09-13 JP JP2021148619A patent/JP7260606B2/ja active Active
- 2021-09-13 FI FIEP21783049.6T patent/FI4214202T3/fi active
- 2021-09-13 KR KR1020237012766A patent/KR20230069983A/ko not_active Ceased
- 2021-09-13 WO PCT/IB2021/058320 patent/WO2022058871A1/en not_active Ceased
- 2021-09-13 PL PL21783049.6T patent/PL4214202T3/pl unknown
- 2021-09-13 US US18/245,039 patent/US12570641B2/en active Active
- 2021-09-14 TW TW112102545A patent/TW202334125A/zh unknown
- 2021-09-14 TW TW110134168A patent/TWI809503B/zh active
-
2022
- 2022-10-27 JP JP2022172594A patent/JP7291839B2/ja active Active
-
2023
- 2023-03-16 ZA ZA2023/03655A patent/ZA202303655B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202216698A (zh) | 2022-05-01 |
| AU2021345531B2 (en) | 2024-02-29 |
| ZA202303655B (en) | 2024-09-25 |
| JP7260606B2 (ja) | 2023-04-18 |
| EP4214202A1 (en) | 2023-07-26 |
| JP2022049005A (ja) | 2022-03-28 |
| CN116507620B (zh) | 2025-11-18 |
| TWI809503B (zh) | 2023-07-21 |
| HUE070846T2 (hu) | 2025-07-28 |
| US12570641B2 (en) | 2026-03-10 |
| PT4214202T (pt) | 2025-04-11 |
| EP4578450A2 (en) | 2025-07-02 |
| AU2021345531A1 (en) | 2023-04-20 |
| ES3022913T3 (en) | 2025-05-29 |
| PL4214202T3 (pl) | 2025-05-19 |
| JP7291839B2 (ja) | 2023-06-15 |
| CN116507620A (zh) | 2023-07-28 |
| EP4214202B1 (en) | 2025-02-26 |
| TW202334125A (zh) | 2023-09-01 |
| WO2022058871A1 (en) | 2022-03-24 |
| JP2022186995A (ja) | 2022-12-15 |
| DK4214202T3 (da) | 2025-03-31 |
| CA3195063A1 (en) | 2022-03-24 |
| MX2023003054A (es) | 2023-04-05 |
| BR112023004713A2 (pt) | 2023-04-18 |
| KR20230069983A (ko) | 2023-05-19 |
| SI4214202T1 (sl) | 2025-05-30 |
| US20230357211A1 (en) | 2023-11-09 |
| EP4578450A3 (en) | 2025-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022049005A5 (enExample) | ||
| JP2022186995A5 (enExample) | ||
| HRP20100166T1 (hr) | Postupak za pripremu 2-aminotiazol-5-aromatičnih karboksamida kao inhibitora kinaze | |
| RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
| MX2020005363A (es) | Compuestos heterociclicos como inhibidores de prmt5. | |
| KR102534266B1 (ko) | 헤테로환형 유도체 및 이의 용도 | |
| FI2534153T4 (fi) | 8-fluori-2-{4-[(metyyliamino}metyyli]fenyyli}-1,3,4,5-tetrahydro-6h-atsepino[5,4,3-cd]indol-6-onin suoloja ja polymorfeja | |
| NZ578876A (en) | 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors | |
| WO2012042539A3 (en) | 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders | |
| JP2015512942A5 (enExample) | ||
| MX2010001745A (es) | Imidazoles fusionados para el tratamiento del cancer. | |
| FI3694863T3 (fi) | Lorlatinibin vapaan emäksen hydraatin kidemuoto | |
| JP2012526808A5 (enExample) | ||
| MX2023009857A (es) | Inhibidores de la glucogeno sintasa 1 (gys1) y metodos de uso de los mismos. | |
| NZ603896A (en) | 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia | |
| JP2024503235A5 (enExample) | ||
| HRP20171895T1 (hr) | Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline | |
| KR101129088B1 (ko) | Ｎ-［6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일］-2-메틸-4'-(트리플루오로메톡시)［1,1'-비페닐］-3-카르복스아미드의 염 | |
| EA200800516A1 (ru) | Производные n-фенил-2-пиримидинамина и процесс их получения | |
| HRP20171041T1 (hr) | Nova sol abeksinostata, s njome povezani kristalni oblik, postupak pripreme i farmaceutske tvari koje ih sadrže | |
| HRP20140409T1 (hr) | Derivat imidazola sa strukturom prolinskog prstena | |
| MX2023014436A (es) | Compuestos de 3-pirrolilsulfonamida como antagonistas de gpr17. | |
| JP2016504325A5 (enExample) | ||
| JP2015502371A5 (enExample) | ||
| WO2014152566A3 (en) | Methods of synthesizing substituted purine compounds |